Table of Contents Author Guidelines Submit a Manuscript
Volume 2011 (2011), Article ID 286875, 4 pages
Clinical Study

Rosiglitazone and Fenofibrate Additive Effects on Lipids

1Cardiology Service, Brooke Army Medical Center, San Antonio, TX 78234-6200, USA
2Cardiology Service MCHE-MDC, Brooke Army Medical Center, 3851 Roger Brooke Drive, San Antonio, TX 78234-6200, USA
3Cardiology Service, Walter Reed Army Medical Center, Bethesda, MD 20889-5600, USA

Received 7 September 2011; Accepted 5 October 2011

Academic Editor: Jeffrey Cohn

Copyright © 2011 Ahmad Slim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. To evaluate the effect of rosiglitazone, fenofibrate, or their combined use on plasma lipids in normoglycemic healthy adults. Methods and Results. Subjects were randomized in a double-blind fashion to rosiglitazone + placebo, fenofibrate + placebo, rosiglitazone + fenofibrate, or matching double placebo. The between-group difference in the change in fasting TG, high-density lipoprotein cholesterol (HDL-C), LDL-C, and plasma apolipoproteins A-I, A-II, and C-III level were compared after 12 weeks of treatment. A total of 548 subjects were screened and 41 met the inclusion criteria. After 12 weeks of therapy, the median change in the triglyceride levels showed a significant reduction ranging from 47 to 55 mg per deciliter in the fenofibrate only and rosiglitazone/fenofibrate groups compared with placebo ( 𝑃 = 0 . 0 4 9 6 ). However, the rosiglitazone only group did not show significant change in triglyceride level. The change in the Apo AII showed increase in all the treatment groups compared with placebo ( 𝑃 = 0 . 0 0 9 ). There was also significant change in the Apo CIII that showed reduction of its level in the fenofibrate only and rosiglitazone/fenofibrate groups ( 𝑃 = 0 . 0 0 0 3 ). Conclusion. Rosiglitazone does not appear to modulate hypertriglyceridemia in patients with elevated triglycerides independent of glucose metabolism.